Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017
Introduction: Co-infection with Tuberculosis and Human Immunodeficiency Virus (TB/HIV) is highly lethal and Africa hosts 74% of cases. In Togo, the prevalence of TB/HIV co-infection was 22% in 2016 with a 42% mortality among the TB/HIV co-infected cases. There is limited data on TB/HIV co-infection...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
African Field Epidemiology Network
2021-12-01
|
| Series: | Journal of Interventional Epidemiology and Public Health |
| Subjects: | |
| Online Access: | https://www.afenet-journal.net/content/article/4/18/full/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151373534920704 |
|---|---|
| author | Agballa Mébiny-Essoh Tchalla Abalo Essona Matatom Akara Toyi Tchamdja Bokoulmé Haienga Kassouta N’tapi Hamadi Assane Péléké Mawaba Hilim Akawulu N’djao Aboudramane Lambonkale Dadou Pikédinam Tchéou Bernard Sawadogo |
| author_facet | Agballa Mébiny-Essoh Tchalla Abalo Essona Matatom Akara Toyi Tchamdja Bokoulmé Haienga Kassouta N’tapi Hamadi Assane Péléké Mawaba Hilim Akawulu N’djao Aboudramane Lambonkale Dadou Pikédinam Tchéou Bernard Sawadogo |
| author_sort | Agballa Mébiny-Essoh Tchalla Abalo |
| collection | DOAJ |
| description | Introduction: Co-infection with Tuberculosis and Human Immunodeficiency Virus (TB/HIV) is highly lethal and Africa hosts 74% of cases. In Togo, the prevalence of TB/HIV co-infection was 22% in 2016 with a 42% mortality among the TB/HIV co-infected cases. There is limited data on TB/HIV co-infection in Centrale health region to inform control and commitment efforts towards end TB by 2030. We aimed to describe epidemiological characteristics, treatment outcomes and identify factors associated with unfavorable outcomes among TB/HIV co-infected cases.
Methods: We conducted a descriptive analysis of secondary data on TB cases recorded in the four Centers of Diagnosis and Treatment (CDTs) of the Togolese Centrale health region from 2008 to 2017. Socio-demographical, clinical and treatment data were collected on a designed questionnaire by reviewing all TB management tools of the four CDTs. We subsequently entered data in Epi-Info-7 and calculated means, ratio and proportions for descriptive analysis. In multivariate analysis, logistic regression was performed to obtain Adjusted Odd Ratio (AOR), 95% Confidence Interval (CI) and p-value to identify factors associated with unfavorable outcomes.
Results: Over the period, 1,448 patients were screened for HIV among 1,825 TB patients recorded. Overall, TB/HIV prevalence was 30.87% (447/1448) range 43.8% in 2008 to 27.6% in 2017 (p=0.01). The mean age of TB/HIV patients varied from 28.80±7.70 years in 2008 to 33.48±8.11 years in 2017. Female to Male sex ratio varied from 9.7 in 2008 to 2.5 in 2017. Pulmonary TB form cases accounted for 94.41% (422/447) of which 74.41% (314/422) were smear positive (SPT+) and 25.59% (108/422) were smear negative, while extra-pulmonary form cases represented 5.59% (25/447). The proportion of TB/HIV patients on Antiretroviral Treatment (ART) varied from 5.25% (2/32) in 2008 to 94.29% (33/35) in 2017. Lost to follow up patients represented 1.57% (7/447) while treatment success rate varied from 62.29% in 2008 to 82.00% in 2017. Case fatality rate decreased from 34.48% in 2008 to 23.53% in 2017. Smear-positive TB (AOR=2.11, 95% CI (1.21-3.60)), TB treatment initiation in the second quarters of the year (AOR=1.71, 95% CI (1.03-2.85)) and having been taken care of between 2015 and 2017 (AOR=1.90, 95% CI (1.14 – 3.12)) were independently associated with unfavorable outcome. When stratified by type of outcome, the absence of ART (AOR=2.62, 95% CI (1.46 – 4.69) were associated with deaths.
Conclusion: TB/HIV co-infection affected young people particularly women with high mortality. The TB form, period of treatment initiation and lack of HIV care influenced treatment outcomes. Systematic HIV screening and ART earlier initiation, practice of DOTS whether based on family or based on caregivers for each patient and caregivers training on TB/HIV co-infection management are necessary to improve patients' survival. |
| format | Article |
| id | doaj-art-5673add7e8a349d8ac33ea560a39cc89 |
| institution | OA Journals |
| issn | 2664-2824 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | African Field Epidemiology Network |
| record_format | Article |
| series | Journal of Interventional Epidemiology and Public Health |
| spelling | doaj-art-5673add7e8a349d8ac33ea560a39cc892025-08-20T02:26:16ZengAfrican Field Epidemiology NetworkJournal of Interventional Epidemiology and Public Health2664-28242021-12-0144https://doi.org/10.37432/jieph.2021.4.4.47Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017Agballa Mébiny-Essoh Tchalla Abalo0Essona Matatom Akara1Toyi Tchamdja2Bokoulmé Haienga3Kassouta N’tapi4Hamadi Assane5Péléké Mawaba Hilim6Akawulu N’djao7Aboudramane Lambonkale8Dadou Pikédinam Tchéou9Bernard Sawadogo10Direction Préfectorale de la Santé de HahoDirection Préfectorale de la Santé de HahoCentre Hospitalier Universitaire de Kara, Faculté de Médecine de l´Université de KaraDirection Préfectorale de la Santé de TchambaDirection régionale de la santé - Région CentraleDivision de la Surveillance Intégrée des Urgences et de la RiposteDirection Préfectorale de la Santé de SotoubouaDirection Préfectorale de la Santé de TchaoudjoDirection Préfectorale de la Santé de DanyDirection Préfectorale de la Santé de BlittaAfrican Field Epidemiology NetworkIntroduction: Co-infection with Tuberculosis and Human Immunodeficiency Virus (TB/HIV) is highly lethal and Africa hosts 74% of cases. In Togo, the prevalence of TB/HIV co-infection was 22% in 2016 with a 42% mortality among the TB/HIV co-infected cases. There is limited data on TB/HIV co-infection in Centrale health region to inform control and commitment efforts towards end TB by 2030. We aimed to describe epidemiological characteristics, treatment outcomes and identify factors associated with unfavorable outcomes among TB/HIV co-infected cases. Methods: We conducted a descriptive analysis of secondary data on TB cases recorded in the four Centers of Diagnosis and Treatment (CDTs) of the Togolese Centrale health region from 2008 to 2017. Socio-demographical, clinical and treatment data were collected on a designed questionnaire by reviewing all TB management tools of the four CDTs. We subsequently entered data in Epi-Info-7 and calculated means, ratio and proportions for descriptive analysis. In multivariate analysis, logistic regression was performed to obtain Adjusted Odd Ratio (AOR), 95% Confidence Interval (CI) and p-value to identify factors associated with unfavorable outcomes. Results: Over the period, 1,448 patients were screened for HIV among 1,825 TB patients recorded. Overall, TB/HIV prevalence was 30.87% (447/1448) range 43.8% in 2008 to 27.6% in 2017 (p=0.01). The mean age of TB/HIV patients varied from 28.80±7.70 years in 2008 to 33.48±8.11 years in 2017. Female to Male sex ratio varied from 9.7 in 2008 to 2.5 in 2017. Pulmonary TB form cases accounted for 94.41% (422/447) of which 74.41% (314/422) were smear positive (SPT+) and 25.59% (108/422) were smear negative, while extra-pulmonary form cases represented 5.59% (25/447). The proportion of TB/HIV patients on Antiretroviral Treatment (ART) varied from 5.25% (2/32) in 2008 to 94.29% (33/35) in 2017. Lost to follow up patients represented 1.57% (7/447) while treatment success rate varied from 62.29% in 2008 to 82.00% in 2017. Case fatality rate decreased from 34.48% in 2008 to 23.53% in 2017. Smear-positive TB (AOR=2.11, 95% CI (1.21-3.60)), TB treatment initiation in the second quarters of the year (AOR=1.71, 95% CI (1.03-2.85)) and having been taken care of between 2015 and 2017 (AOR=1.90, 95% CI (1.14 – 3.12)) were independently associated with unfavorable outcome. When stratified by type of outcome, the absence of ART (AOR=2.62, 95% CI (1.46 – 4.69) were associated with deaths. Conclusion: TB/HIV co-infection affected young people particularly women with high mortality. The TB form, period of treatment initiation and lack of HIV care influenced treatment outcomes. Systematic HIV screening and ART earlier initiation, practice of DOTS whether based on family or based on caregivers for each patient and caregivers training on TB/HIV co-infection management are necessary to improve patients' survival.https://www.afenet-journal.net/content/article/4/18/full/tuberculosishivco-infectioncentral health regiontogo |
| spellingShingle | Agballa Mébiny-Essoh Tchalla Abalo Essona Matatom Akara Toyi Tchamdja Bokoulmé Haienga Kassouta N’tapi Hamadi Assane Péléké Mawaba Hilim Akawulu N’djao Aboudramane Lambonkale Dadou Pikédinam Tchéou Bernard Sawadogo Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 Journal of Interventional Epidemiology and Public Health tuberculosis hiv co-infection central health region togo |
| title | Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 |
| title_full | Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 |
| title_fullStr | Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 |
| title_full_unstemmed | Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 |
| title_short | Epidemiological profile, treatment outcomes and factors associated with unfavorable treatment outcomes among patients co-infected with Tuberculosis and Human Immunodeficiency Virus in the Centrale Health Region in Togo, 2008 – 2017 |
| title_sort | epidemiological profile treatment outcomes and factors associated with unfavorable treatment outcomes among patients co infected with tuberculosis and human immunodeficiency virus in the centrale health region in togo 2008 2017 |
| topic | tuberculosis hiv co-infection central health region togo |
| url | https://www.afenet-journal.net/content/article/4/18/full/ |
| work_keys_str_mv | AT agballamebinyessohtchallaabalo epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT essonamatatomakara epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT toyitchamdja epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT bokoulmehaienga epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT kassoutantapi epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT hamadiassane epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT pelekemawabahilim epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT akawulundjao epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT aboudramanelambonkale epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT dadoupikedinamtcheou epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 AT bernardsawadogo epidemiologicalprofiletreatmentoutcomesandfactorsassociatedwithunfavorabletreatmentoutcomesamongpatientscoinfectedwithtuberculosisandhumanimmunodeficiencyvirusinthecentralehealthregionintogo20082017 |